274 related articles for article (PubMed ID: 29203461)
21. Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.
Grob TJ; Heilenkötter U; Geist S; Paluchowski P; Wilke C; Jaenicke F; Quaas A; Wilczak W; Choschzick M; Sauter G; Lebeau A
Breast Cancer Res Treat; 2012 Jul; 134(2):561-7. PubMed ID: 22610646
[TBL] [Abstract][Full Text] [Related]
22. p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer.
Powell E; Shao J; Yuan Y; Chen HC; Cai S; Echeverria GV; Mistry N; Decker KF; Schlosberg C; Do KA; Edwards JR; Liang H; Piwnica-Worms D; Piwnica-Worms H
Breast Cancer Res; 2016 Jan; 18(1):13. PubMed ID: 26818199
[TBL] [Abstract][Full Text] [Related]
23. Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences.
Kriegsmann M; Endris V; Wolf T; Pfarr N; Stenzinger A; Loibl S; Denkert C; Schneeweiss A; Budczies J; Sinn P; Weichert W
Oncotarget; 2014 Oct; 5(20):9952-65. PubMed ID: 25296970
[TBL] [Abstract][Full Text] [Related]
24. The MSP-RON axis stimulates cancer cell growth in models of triple negative breast cancer.
Millar R; Kilbey A; Remak SJ; Severson TM; Dhayade S; Sandilands E; Foster K; Bryant DM; Blyth K; Coffelt SB
Mol Oncol; 2020 Aug; 14(8):1868-1880. PubMed ID: 32484599
[TBL] [Abstract][Full Text] [Related]
25. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
Costa RLB; Han HS; Gradishar WJ
Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
[TBL] [Abstract][Full Text] [Related]
26. Germline TP53 and MSH6 mutations implicated in sporadic triple-negative breast cancer (TNBC): a preliminary study.
Yi D; Xu L; Luo J; You X; Huang T; Zi Y; Li X; Wang R; Zhong Z; Tang X; Li A; Shi Y; Rao J; Zhang Y; Sang J
Hum Genomics; 2019 Jan; 13(1):4. PubMed ID: 30630526
[TBL] [Abstract][Full Text] [Related]
27. Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.
Santarpia L; Bottai G; Kelly CM; Győrffy B; Székely B; Pusztai L
Oncologist; 2016 Sep; 21(9):1063-78. PubMed ID: 27384237
[TBL] [Abstract][Full Text] [Related]
28. Somatic gene mutation analysis of triple negative breast cancers.
Dillon JL; Mockus SM; Ananda G; Spotlow V; Wells WA; Tsongalis GJ; Marotti JD
Breast; 2016 Oct; 29():202-7. PubMed ID: 27397723
[TBL] [Abstract][Full Text] [Related]
29. Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations.
Kim J; Jeong K; Jun H; Kim K; Bae JM; Song MG; Yi H; Park S; Woo GU; Lee DW; Kim TY; Lee KH; Im SA
Hum Genomics; 2023 Jan; 17(1):2. PubMed ID: 36604691
[TBL] [Abstract][Full Text] [Related]
30. A mouse model featuring tissue-specific deletion of p53 and Brca1 gives rise to mammary tumors with genomic and transcriptomic similarities to human basal-like breast cancer.
Hollern DP; Contreras CM; Dance-Barnes S; Silva GO; Pfefferle AD; Xiong J; Darr DB; Usary J; Mott KR; Perou CM
Breast Cancer Res Treat; 2019 Feb; 174(1):143-155. PubMed ID: 30484104
[TBL] [Abstract][Full Text] [Related]
31. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
32. P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.
Shapira I; Lee A; Vora R; Budman DR
Crit Rev Oncol Hematol; 2013 Nov; 88(2):284-92. PubMed ID: 23755891
[TBL] [Abstract][Full Text] [Related]
33. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
Zhang H; Cohen AL; Krishnakumar S; Wapnir IL; Veeriah S; Deng G; Coram MA; Piskun CM; Longacre TA; Herrler M; Frimannsson DO; Telli ML; Dirbas FM; Matin AC; Dairkee SH; Larijani B; Glinsky GV; Bild AH; Jeffrey SS
Breast Cancer Res; 2014 Apr; 16(2):R36. PubMed ID: 24708766
[TBL] [Abstract][Full Text] [Related]
34. Natural History of Germline BRCA1 Mutated and BRCA Wild-type Triple-negative Breast Cancer.
Gardi N; Chaubal R; Parab P; Pachakar S; Kulkarni S; Shet T; Joshi S; Kembhavi Y; Chandrani P; Quist J; Kowtal P; Grigoriadis A; Sarin R; Govindarajan R; Gupta S
Cancer Res Commun; 2024 Feb; 4(2):404-417. PubMed ID: 38315150
[TBL] [Abstract][Full Text] [Related]
35. Common Genomic Aberrations in Mouse and Human Breast Cancers with Concurrent P53 Deficiency and Activated PTEN-PI3K-AKT Pathway.
Martinez JD; Mo Q; Xu Y; Qin L; Li Y; Xu J
Int J Biol Sci; 2022; 18(1):229-241. PubMed ID: 34975329
[TBL] [Abstract][Full Text] [Related]
36. Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response.
Lips EH; Michaut M; Hoogstraat M; Mulder L; Besselink NJ; Koudijs MJ; Cuppen E; Voest EE; Bernards R; Nederlof PM; Wesseling J; Rodenhuis S; Wessels LF;
Breast Cancer Res; 2015 Oct; 17(1):134. PubMed ID: 26433948
[TBL] [Abstract][Full Text] [Related]
37. Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women.
Tilch E; Seidens T; Cocciardi S; Reid LE; Byrne D; Simpson PT; Vargas AC; Cummings MC; Fox SB; Lakhani SR; Chenevix Trench G
Breast Cancer Res Treat; 2014 Jan; 143(2):385-92. PubMed ID: 24318467
[TBL] [Abstract][Full Text] [Related]
38. Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer.
Knight JF; Lesurf R; Zhao H; Pinnaduwage D; Davis RR; Saleh SM; Zuo D; Naujokas MA; Chughtai N; Herschkowitz JI; Prat A; Mulligan AM; Muller WJ; Cardiff RD; Gregg JP; Andrulis IL; Hallett MT; Park M
Proc Natl Acad Sci U S A; 2013 Apr; 110(14):E1301-10. PubMed ID: 23509284
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes.
Basho RK; Zhao L; White JB; Huo L; Bassett RL; Mittendorf EA; Thompson A; Litton JK; Ueno N; Arun B; Lim B; Valero V; Tripathy D; Zhang J; Adrada BE; Santiago L; Ravenberg E; Seth S; Yam C; Moulder SL; Damodaran S
JCO Precis Oncol; 2024 Mar; 8():e2300124. PubMed ID: 38484209
[TBL] [Abstract][Full Text] [Related]
40. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
Bennett CN; Tomlinson CC; Michalowski AM; Chu IM; Luger D; Mittereder LR; Aprelikova O; Shou J; Piwinica-Worms H; Caplen NJ; Hollingshead MG; Green JE
Breast Cancer Res; 2012 Jul; 14(4):R109. PubMed ID: 22812567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]